IMMPACT BIO
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
IMMPACT BIO
Industry:
Biotechnology Life Science
Founded:
2017-01-01
Address:
Camarillo, California, United States
Country:
United States
Website Url:
http://www.immpact-bio.com
Total Employee:
11+
Status:
Active
Total Funding:
129 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Advisors List
Board_member
Board_member
2022-01-01
Board_member
2022-01-01
Board_member
Board_member
2022-01-01
Current Employees Featured
Vikram Lamba Chief Financial Officer and Head of Business Development @ ImmPACT Bio
Chief Financial Officer and Head of Business Development
2022-08-01
Gideon Gross Co-Founder @ ImmPACT Bio
Co-Founder
Zelig Eshhar Co-Founder @ ImmPACT Bio
Co-Founder
Marc Better Acting CTO @ ImmPACT Bio
Acting CTO
Richard Kendall CSO @ ImmPACT Bio
CSO
Sumant Ramachandra President and chief executive officer @ ImmPACT Bio
President and chief executive officer
Anat Nursella Chief Financial Officer @ ImmPACT Bio
Chief Financial Officer
2020-11-01
Venkat Yepuri COO @ ImmPACT Bio
COO
2022-04-01
Founder
Investors List
Foresite Capital
Foresite Capital investment in Series B - ImmPACT Bio
Bukwang Pharmaceutical Co
Bukwang Pharmaceutical Co investment in Series B - ImmPACT Bio
Surveyor Capital
Surveyor Capital investment in Series B - ImmPACT Bio
RM Global Partners
RM Global Partners investment in Series B - ImmPACT Bio
Decheng Capital
Decheng Capital investment in Series B - ImmPACT Bio
OrbiMed
OrbiMed investment in Series B - ImmPACT Bio
Novartis Venture Fund
Novartis Venture Fund investment in Series B - ImmPACT Bio
venBio Partners
venBio Partners investment in Series B - ImmPACT Bio
JVC Investment Partners
JVC Investment Partners investment in Series A - ImmPACT Bio
RM Global Partners
RM Global Partners investment in Series A - ImmPACT Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-09 | ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development |
| 2022-04-19 | ImmPACT Bio Names Venkat Yepuri as Chief Operating Officer |
Official Site Inspections
http://www.immpact-bio.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImmPACT Bio"
About - ImmPACT Bio
Jonathan Benjamin is a hematologist, oncologist, and immunologist. Prior to joining ImmPACT in September 2022 as CMO, Dr. Benjamin was Senior Vice President for Clinical Research at …See details»
Home Page - ImmPACT Bio
“>”>Logic-Gated Cell Therapies for Unmet Medical Needs “>”>We are developing the Next Generation of Cell Therapies How we help our patients Learn more about us Our ImmPACT …See details»
ImmPACT Bio - Crunchbase Company Profile & Funding
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, …See details»
ImmPACT Bio - LinkedIn
About ImmPACT Bio: ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key …See details»
ImmPACT Bio Company Profile 2025: Valuation, …
ImmPACT Bio was founded in 2017. Where is ImmPACT Bio headquartered? ImmPACT Bio is headquartered in West Hills, CA. What is the size of ImmPACT Bio? ImmPACT Bio has 106 total employees. What industry is ImmPACT Bio …See details»
ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D.
Sep 22, 2022 “On behalf of the entire ImmPACT Bio organization and board of directors, I am thrilled to welcome Jonathan as our chief medical officer,” said Sumant Ramachandra, M.D., Ph.D., M.B.A., president and CEO of ImmPACT …See details»
ImmPACT Bio - Israeli Startup | Startup Nation Finder
Feb 8, 2023 ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor …See details»
Careers - ImmPACT Bio
ImmPACT Bio USA, Inc. is an E-Verify participating employer. Candidates will be required to show proof of being vaccinated against COVID-19 upon commencing employment. …See details»
ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as …
Oct 31, 2023 ImmPACT Bio is pioneering the development of the first-and-only CD19/CD20 CAR T-cell therapy for the treatment of both B-cell driven malignancies and autoimmune diseases,” said Dr. Lee. “ImmPACT Bio’s …See details»
ImmPACT Bio - Contacts, Employees, Board Members, Advisors
Organization. ImmPACT Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Number of …See details»
ImmPACT-Bio Company Profile - Office Locations, Competitors
ImmPACT-Bio has 5 employees across 2 locations and $18 m in total funding,. See insights on ImmPACT-Bio including office locations, competitors, revenue, financials, executives, …See details»
ImmPACT Bio - Funding, Financials, Valuation & Investors
ImmPACT Bio USA is developing novel cell therapies for treating cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. ...See details»
Jonathan Benjamin - ImmPACT Bio
Jonathan Benjamin is a hematologist, oncologist, and immunologist. Prior to joining ImmPACT in September 2022 as CMO, Dr. Benjamin was Senior Vice President for Clinical Research at …See details»
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its …
Oct 25, 2024 SOUTH SAN FRANCISCO, CA, USA I October 24, 2024 I Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to …See details»
ImmPACT Bio acquired by Lyell Immunopharma - Crunchbase
Oct 24, 2024 Lyell Immunopharma acquires ImmPACT Bio on 2024-10-24 for an undisclosed amountSee details»
ImmPACT Bio - VentureRadar
ImmPACT-Bio is developing a novel Chimeric Antigen Receptor T-cell (CAR-T) strategy that uniquely differentiates cancerous from non-cancerous tissues, and specifically addresses a …See details»
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Aug 18, 2020 ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The company was founded …See details»
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
Feb 8, 2023 —Seasoned executive brings decades of experience in capital markets, finance, and corporate strategy. WEST HILLS, Calif., Feb. 8, 2023 /PRNewswire/ — ImmPACT Bio …See details»
ImmPACT Bio Closes $111 Million Series B Financing, Names New …
Jan 20, 2022 ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have …See details»
ImmPACT Bio Announces Completion of Merger with Kalthera to …
Jul 27, 2021 – Enhances ImmPACT Bio’s pipeline with promising clinical candidates including bispecific CAR T-cell therapy candidate in B-cell lymphoma – CAMARILLO, Calif., July 22, …See details»